References
- Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Cancer statistics, 2006. CA Cancer J Clin 2006;56:106–30.
- LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAP) and their emerging role in cancer. Oncogene 1998;17:3247–59.
- Li F. Survivin study: what is the next wave. J Cell Physiol 2003;197:8–29.
- Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917–21.
- Dong Y, Sui L, Watanabe Y, Sugimoto K, Tokuda M. Survivin expression in laryngeal squamous cell carcinomas and its prognostic implications. Anticancer Res 2002;22:2377–84.
- Muzio LL, Pannone G, Staibano S, Mignogna MD, Rubini C, Mariggio MA, Survivin expression in oral squamous cell carcinoma. Br J Cancer 2003;89:2244–8.
- Muzio LL, Farina A, Rubini C, Pezzetti F, Stabellini G, Laino G, Survivin as prognostic factor in squamous cell carcinoma of the oral cavity. Cancer Lett 2005;225:27–33.
- Sahin U, Tureci OE, Schmitt H, Cochlovius B, Johannes T, Schmits R, Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A 1995;92:11810–13.
- Angelopoulou K, Diamandis E, Sutherland DJA, Kellen JA, Bunting PS. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 1994;58:480–7.
- Eto M, Kodama S, Uemura N, Suzuki M. Antibody responses to survivin and their clinical significance in patients with head and neck cancer. Head Neck 2007;29:1128–35.
- Chang JT, Wong FH, Liao CT, Chen IH, Wang HM, Cheng AJ. Enzyme immunoassay for serum autoantibody to survivin and its findings in head-and-neck cancer patients. Clin Chem 2004;50:1261–4.
- Rohayem J, Diestelkoetter P, Weigle B, Oehmichen A, Schmitz M, Mehlhorn J, Antibody responses to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res 2000;60:1815–17.
- Yagihashi A, Asanuma K, Nakamura M, Araya J, Mano Y, Torigoe T, Detection of anti-survivin antibody in gastrointestinal cancer patients. Clin Chem 2001;47:1729–31.
- Yagihashi A, Ohmura T, Asanuma K, Kobatashi D, Tsuji N, Torigoe T, Detection of autoantibodies to survivin and livin in sera from patients with breast cancer. Clin Chim Acta 2005;362:125–30.
- Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 2007;92:271–8.
- Schmidt SM, Schag K, Muller MR, Weck MM, Appel S, Kanz L, Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 2003;102:571–6.
- Gasco M, Crook T. The p53 network in head and neck cancer. Oral Oncol 2003;39:222–31.
- Hirohashi Y, Torigoe T, Maeda A, Nabeta Y, Kamiguchi K, Sato T, An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 2002;8:1731–9.
- Recker S, Meier A, Holten-Anderson L, Svane IM, Becker JC, Straten PT, Identification of novel survivin-derived CTL epitopes. Cancer Biol Ther 2004;3:173–9.
- Tas F, Duranyildiz D, Argon A, Oguz H, Camlica H, Yasasever V, Serum bcl-2 and survivin levels in melanoma. Melanoma Res 2004;14:543–6.